Medically treated prolactin-secreting pituitary adenomas: When should we operate?

Fernando Vale Diaz, Armen R. Deukmedjian, Shan Hann, Vitra Shah, Anthony D. Morrison

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background. The incidence of medical failure for prolactin (PRL)-secreting pituitary tumours is not well known. Object. The purpose of this study is to report clinical, radiographic and laboratory findings of PRL-secreting tumours that predict failed medical management. Methods. An analysis of 92 consecutive patients was performed that met the inclusion criteria. Decision for surgery was made based on failure of dopamine agonists to either control clinical symptoms and normalise hormonal level or diminish mass effect on follow-up evaluation. Results. Of the 92 patients treated, 14 patients (15%) required trans-nasal, trans-sphenoidal pituitary surgery (TSS). One patient underwent surgery for repair of a skull defect and 13 patients (14%) required surgery after failed medical management. Higher initial PRL was statistically significant regarding the need for surgical intervention, but a persistently abnormal level after initiation of treatment was a more significant predictor (Fisher exact test, p=0.005 vs. p<0.001). Size was also a statistically significant factor (p=0.014); macroadenomas had a relative risk of 9.27 (95% CI: 1.15-74.86) for needing surgery compared to microadenomas. In addition, macroadenomas with cavernous sinus (CS) extension and pre-operative visual field deficit demonstrated a strong tendency for surgical intervention. Conclusion. Medical management remains the most effective treatment option for prolactinomas. A partial hormonal response to medical management seems to be the most significant predictive factor but adenomas>20 mm, visual field deficit and invasion of the CS may help predict the need for surgery. We suggest a minimum trial period (at least 8 weeks) of medical treatment prior to the consideration of surgery.

Original languageEnglish (US)
Pages (from-to)56-62
Number of pages7
JournalBritish Journal of Neurosurgery
Volume27
Issue number1
DOIs
StatePublished - Feb 1 2013

Fingerprint

Prolactinoma
Prolactin
Dopamine Agonists
Pituitary Neoplasms
Visual Fields
Nose
Skull
Incidence
Therapeutics
Neoplasms

Keywords

  • Pituitary surgery
  • Prolactinoma
  • Surgical indications

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Medically treated prolactin-secreting pituitary adenomas : When should we operate? / Vale Diaz, Fernando; Deukmedjian, Armen R.; Hann, Shan; Shah, Vitra; Morrison, Anthony D.

In: British Journal of Neurosurgery, Vol. 27, No. 1, 01.02.2013, p. 56-62.

Research output: Contribution to journalArticle

Vale Diaz, Fernando ; Deukmedjian, Armen R. ; Hann, Shan ; Shah, Vitra ; Morrison, Anthony D. / Medically treated prolactin-secreting pituitary adenomas : When should we operate?. In: British Journal of Neurosurgery. 2013 ; Vol. 27, No. 1. pp. 56-62.
@article{806346a3c77d42fc8b7fa703cd4dd99c,
title = "Medically treated prolactin-secreting pituitary adenomas: When should we operate?",
abstract = "Background. The incidence of medical failure for prolactin (PRL)-secreting pituitary tumours is not well known. Object. The purpose of this study is to report clinical, radiographic and laboratory findings of PRL-secreting tumours that predict failed medical management. Methods. An analysis of 92 consecutive patients was performed that met the inclusion criteria. Decision for surgery was made based on failure of dopamine agonists to either control clinical symptoms and normalise hormonal level or diminish mass effect on follow-up evaluation. Results. Of the 92 patients treated, 14 patients (15{\%}) required trans-nasal, trans-sphenoidal pituitary surgery (TSS). One patient underwent surgery for repair of a skull defect and 13 patients (14{\%}) required surgery after failed medical management. Higher initial PRL was statistically significant regarding the need for surgical intervention, but a persistently abnormal level after initiation of treatment was a more significant predictor (Fisher exact test, p=0.005 vs. p<0.001). Size was also a statistically significant factor (p=0.014); macroadenomas had a relative risk of 9.27 (95{\%} CI: 1.15-74.86) for needing surgery compared to microadenomas. In addition, macroadenomas with cavernous sinus (CS) extension and pre-operative visual field deficit demonstrated a strong tendency for surgical intervention. Conclusion. Medical management remains the most effective treatment option for prolactinomas. A partial hormonal response to medical management seems to be the most significant predictive factor but adenomas>20 mm, visual field deficit and invasion of the CS may help predict the need for surgery. We suggest a minimum trial period (at least 8 weeks) of medical treatment prior to the consideration of surgery.",
keywords = "Pituitary surgery, Prolactinoma, Surgical indications",
author = "{Vale Diaz}, Fernando and Deukmedjian, {Armen R.} and Shan Hann and Vitra Shah and Morrison, {Anthony D.}",
year = "2013",
month = "2",
day = "1",
doi = "10.3109/02688697.2012.714817",
language = "English (US)",
volume = "27",
pages = "56--62",
journal = "British Journal of Neurosurgery",
issn = "0268-8697",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Medically treated prolactin-secreting pituitary adenomas

T2 - When should we operate?

AU - Vale Diaz, Fernando

AU - Deukmedjian, Armen R.

AU - Hann, Shan

AU - Shah, Vitra

AU - Morrison, Anthony D.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Background. The incidence of medical failure for prolactin (PRL)-secreting pituitary tumours is not well known. Object. The purpose of this study is to report clinical, radiographic and laboratory findings of PRL-secreting tumours that predict failed medical management. Methods. An analysis of 92 consecutive patients was performed that met the inclusion criteria. Decision for surgery was made based on failure of dopamine agonists to either control clinical symptoms and normalise hormonal level or diminish mass effect on follow-up evaluation. Results. Of the 92 patients treated, 14 patients (15%) required trans-nasal, trans-sphenoidal pituitary surgery (TSS). One patient underwent surgery for repair of a skull defect and 13 patients (14%) required surgery after failed medical management. Higher initial PRL was statistically significant regarding the need for surgical intervention, but a persistently abnormal level after initiation of treatment was a more significant predictor (Fisher exact test, p=0.005 vs. p<0.001). Size was also a statistically significant factor (p=0.014); macroadenomas had a relative risk of 9.27 (95% CI: 1.15-74.86) for needing surgery compared to microadenomas. In addition, macroadenomas with cavernous sinus (CS) extension and pre-operative visual field deficit demonstrated a strong tendency for surgical intervention. Conclusion. Medical management remains the most effective treatment option for prolactinomas. A partial hormonal response to medical management seems to be the most significant predictive factor but adenomas>20 mm, visual field deficit and invasion of the CS may help predict the need for surgery. We suggest a minimum trial period (at least 8 weeks) of medical treatment prior to the consideration of surgery.

AB - Background. The incidence of medical failure for prolactin (PRL)-secreting pituitary tumours is not well known. Object. The purpose of this study is to report clinical, radiographic and laboratory findings of PRL-secreting tumours that predict failed medical management. Methods. An analysis of 92 consecutive patients was performed that met the inclusion criteria. Decision for surgery was made based on failure of dopamine agonists to either control clinical symptoms and normalise hormonal level or diminish mass effect on follow-up evaluation. Results. Of the 92 patients treated, 14 patients (15%) required trans-nasal, trans-sphenoidal pituitary surgery (TSS). One patient underwent surgery for repair of a skull defect and 13 patients (14%) required surgery after failed medical management. Higher initial PRL was statistically significant regarding the need for surgical intervention, but a persistently abnormal level after initiation of treatment was a more significant predictor (Fisher exact test, p=0.005 vs. p<0.001). Size was also a statistically significant factor (p=0.014); macroadenomas had a relative risk of 9.27 (95% CI: 1.15-74.86) for needing surgery compared to microadenomas. In addition, macroadenomas with cavernous sinus (CS) extension and pre-operative visual field deficit demonstrated a strong tendency for surgical intervention. Conclusion. Medical management remains the most effective treatment option for prolactinomas. A partial hormonal response to medical management seems to be the most significant predictive factor but adenomas>20 mm, visual field deficit and invasion of the CS may help predict the need for surgery. We suggest a minimum trial period (at least 8 weeks) of medical treatment prior to the consideration of surgery.

KW - Pituitary surgery

KW - Prolactinoma

KW - Surgical indications

UR - http://www.scopus.com/inward/record.url?scp=84872722025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872722025&partnerID=8YFLogxK

U2 - 10.3109/02688697.2012.714817

DO - 10.3109/02688697.2012.714817

M3 - Article

C2 - 22938595

AN - SCOPUS:84872722025

VL - 27

SP - 56

EP - 62

JO - British Journal of Neurosurgery

JF - British Journal of Neurosurgery

SN - 0268-8697

IS - 1

ER -